Resource Summary Report

Generated by RRID on Jul 7, 2024

CD11b-APC, human and mouse

RRID:AB_2654646
Type: Antibody

Proper Citation

(Miltenyi Biotec Cat# 130-109-364, RRID:AB_2654646)

Antibody Information

URL: http://antibodyregistry.org/AB_2654646

Proper Citation: (Miltenyi Biotec Cat# 130-109-364, RRID:AB_2654646)

Target Antigen: CD11b

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 2-2018; Target Distribution myeloid cells, NK cells, microglia, lymphocytes, monocytes, macrophages; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-802. (RRID:AB_2726324).

Antibody Name: CD11b-APC, human and mouse

Description: This monoclonal targets CD11b

Target Organism: human, mouse

Clone ID: REA592

Antibody ID: AB_2654646

Vendor: Miltenyi Biotec

Catalog Number: 130-109-364

Record Creation Time: 20231110T034440+0000

Record Last Update: 20240530T221043+0000

Ratings and Alerts

No rating or validation information has been found for CD11b-APC, human and mouse.

Warning: Discontinued: 2021
Discontinued: 2-2018; Target Distribution myeloid cells, NK cells, microglia, lymphocytes, monocytes, macrophages; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-802. (RRID:AB_2726324).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID.

Zhou Z, et al. (2024) Rebalancing TGF-?/PGE2 breaks RT-induced immunosuppressive barriers by enhancing tumor-infiltrated dendritic cell homing. International journal of biological sciences, 20(1), 367.

Tilsed CM, et al. (2022) CD4+ T cells drive an inflammatory, TNF-?/IFN-rich tumor microenvironment responsive to chemotherapy. Cell reports, 41(13), 111874.